Tags

Type your tag names separated by a space and hit enter

Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9.
Pancreas. 2009 Jul; 38(5):534-41.P

Abstract

OBJECTIVE

We followed up the presence of Kirsten rat sarcoma (K-ras) mutations in plasma DNA and assessed its clinical value in patients with pancreatic cancer.

METHODS

Plasma samples (N = 430) of 56 patients with pancreatic cancer and 13 patients with pancreatitis were analyzed by real-time polymerase chain reaction using peptide nucleic acid-mediated polymerase chain reaction clamping.

RESULTS

K-ras mutations could be detected in the plasma DNA of 20 patients with cancer (36%). No K-ras mutation was found in the plasma of patients with pancreatitis. In 7 (35%) of 20 patients with lowly or moderately elevated carbohydrate antigen 19.9 (CA 19-9) levels lower than 100 U/mL, the result of the assay was positive for K-ras mutation. The combination of K-ras and CA 19-9 level determination gave a sensitivity for the diagnosis of pancreatic cancer of 91% (40/44) of the patients. Thirteen of 35 patients with pancreatic cancer (102 plasma samples) with elevated CA 19-9 levels (>35 U/mL) and altered K-ras gene showed significant correlation with elevated CA 19-9 levels (P=0.048).

CONCLUSIONS

The summary of our approach of noninvasive, convenient, extremely high-sensitive K-ras mutation analysis in plasma might provide diagnostic and prognostic information to clinicians but will not be sufficient in a standardized early diagnosis of pancreatic carcinoma. The combination with CA 19-9 assay is useful for detection and prognostic evaluation of pancreatic carcinoma.

Authors+Show Affiliations

Department of Medical Oncology and Hematology, Charité School of Medicine, Campus Virchow-Klinikum, Humboldt University of Berlin, Berlin, Germany. Jan.Daebritz@charite.deNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19295453

Citation

Däbritz, Jan, et al. "Follow-up Study of K-ras Mutations in the Plasma of Patients With Pancreatic Cancer: Correlation With Clinical Features and Carbohydrate Antigen 19-9." Pancreas, vol. 38, no. 5, 2009, pp. 534-41.
Däbritz J, Preston R, Hänfler J, et al. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. Pancreas. 2009;38(5):534-41.
Däbritz, J., Preston, R., Hänfler, J., & Oettle, H. (2009). Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. Pancreas, 38(5), 534-41. https://doi.org/10.1097/MPA.0b013e31819f6376
Däbritz J, et al. Follow-up Study of K-ras Mutations in the Plasma of Patients With Pancreatic Cancer: Correlation With Clinical Features and Carbohydrate Antigen 19-9. Pancreas. 2009;38(5):534-41. PubMed PMID: 19295453.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. AU - Däbritz,Jan, AU - Preston,Roman, AU - Hänfler,Joachim, AU - Oettle,Helmut, PY - 2009/3/20/entrez PY - 2009/3/20/pubmed PY - 2009/9/26/medline SP - 534 EP - 41 JF - Pancreas JO - Pancreas VL - 38 IS - 5 N2 - OBJECTIVE: We followed up the presence of Kirsten rat sarcoma (K-ras) mutations in plasma DNA and assessed its clinical value in patients with pancreatic cancer. METHODS: Plasma samples (N = 430) of 56 patients with pancreatic cancer and 13 patients with pancreatitis were analyzed by real-time polymerase chain reaction using peptide nucleic acid-mediated polymerase chain reaction clamping. RESULTS: K-ras mutations could be detected in the plasma DNA of 20 patients with cancer (36%). No K-ras mutation was found in the plasma of patients with pancreatitis. In 7 (35%) of 20 patients with lowly or moderately elevated carbohydrate antigen 19.9 (CA 19-9) levels lower than 100 U/mL, the result of the assay was positive for K-ras mutation. The combination of K-ras and CA 19-9 level determination gave a sensitivity for the diagnosis of pancreatic cancer of 91% (40/44) of the patients. Thirteen of 35 patients with pancreatic cancer (102 plasma samples) with elevated CA 19-9 levels (>35 U/mL) and altered K-ras gene showed significant correlation with elevated CA 19-9 levels (P=0.048). CONCLUSIONS: The summary of our approach of noninvasive, convenient, extremely high-sensitive K-ras mutation analysis in plasma might provide diagnostic and prognostic information to clinicians but will not be sufficient in a standardized early diagnosis of pancreatic carcinoma. The combination with CA 19-9 assay is useful for detection and prognostic evaluation of pancreatic carcinoma. SN - 1536-4828 UR - https://www.unboundmedicine.com/medline/citation/19295453/Follow_up_study_of_K_ras_mutations_in_the_plasma_of_patients_with_pancreatic_cancer:_correlation_with_clinical_features_and_carbohydrate_antigen_19_9_ L2 - https://doi.org/10.1097/MPA.0b013e31819f6376 DB - PRIME DP - Unbound Medicine ER -